Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,666 total articles
Fate Therapeutics showcased early Phase 1 clinical data for its off-the-shelf CAR T-cell therapy FT836 at the ASCO Annual Meeting, highlighting meaningful tumor reductions in KRAS wild-type metastatic colorectal cancer patients without the need for conditioning chemotherapy. The therapy utilizes novel Sword and Shield technology, enabling persisten…
IperionX Limited announced that titanium fasteners produced with its patented technologies performed substantially better than high-strength SAE Grade 8 steel fasteners in independent tests conducted by the U.S. Army DEVCOM Ground Vehicle Systems Center and Westmoreland Mechanical Testing & Research. The titanium fasteners demonstrated superior tor…
Mixed Martial Arts Group Limited (NYSE American: MMA), operating as MMA.INC, announced that Conor McGregor's return to UFC competition on July 11, 2026 has triggered unprecedented ticket demand and global fan engagement. As McGregor serves as both investor and strategic advisor, the company aims to capitalize on the heightened attention through its…
Celcuity Inc., a clinical-stage biotech company, announced a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial. This trial evaluates Gedatolisib, a novel PI3K/mTOR inhibitor, in combination regimens for treating hormone receptor positive, HER2-negative advanced breast cancer. …
Cosmos Health Inc. (NASDAQ:COSM) announced its entry into the global animal health sector by launching a veterinary formulation of its antimicrobial product C-Scrub Wash 4%. The product has passed stringent European veterinary disinfectant standards (EN 1656 and EN 1657) and is set to launch first in the UK, with plans for international expansion. …
Jiuzi Holdings announced significant progress in developing its AI intelligent imaging and data platform, moving forward with plans for commercial deployment. The platform integrates AI recognition, data processing, and cloud architecture to provide scalable, real-time analytics solutions designed for enterprise clients. Key features include facial…
Greenwich LifeSciences reports promising open-label data from their Phase III FLAMINGO-01 clinical trial evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrences. Preliminary results show a statistically significant increase in injection site immune reactions after multiple vaccinations in a non-HLA-A*02 patient arm, supp…
Osisko Development Corp. has completed a US$300 million offering of 4.125% convertible senior notes due 2031, including the full exercise of initial purchaser options and a private placement with Double Zero Capital. The proceeds, net of costs for capped call transactions to mitigate dilution, will fund the development and pre-construction activiti…
Alpha Modus Holdings announces that holders of its Alpha Cash Prepaid Mastercard will receive a $2.50 monthly rebate when spending $10 or more on public transit across 11 major U.S. metropolitan areas via Mastercard's Public Transit Benefit. This program targets unbanked and underbanked consumers, offering them rewards previously unavailable throug…
LifeMD, a Nasdaq-listed telehealth company, announced the immediate appointment of Umesh Sripad as Chief Technology Officer. Mr. Sripad brings over 20 years of experience in digital transformation and technology leadership from major consumer and healthcare-related companies. His role will focus on leading LifeMD's technology strategy, platform tra…
MBX Biosciences announced it will present new Phase 2 and one-year extension data on its once-weekly canvuparatide treatment for chronic hypoparathyroidism at the Endocrine Society's Annual Meeting (ENDO 2026). The company will also host an investor webcast to discuss the clinical trial results, highlighting progress toward Phase 3 development.
NuCana plc, a clinical-stage biopharmaceutical company focused on cancer treatments, has appointed Ian Webster as Chief Financial Officer. Webster, formerly Interim CFO and Director of Finance, brings extensive financial and biopharmaceutical sector experience. His appointment comes as NuCana advances its Phase 2 clinical studies for NUC-7738 and N…
Nasus Pharma announces a virtual key opinion leader event on June 10, 2026, to present NS002, its intranasal epinephrine powder for anaphylaxis treatment, featuring expert discussion of Phase 2 data showing faster and higher absorption compared to EpiPen. The event aims to showcase NS002's potential as a needle-free alternative addressing unmet med…
Aprea Therapeutics presented updated Phase 1 clinical trial data for their oral WEE1 inhibitor, APR-1051, at ASCO 2026. The data demonstrated preliminary anti-tumor activity, including partial responses and stable disease in heavily pretreated patients with advanced solid tumors, along with a favorable safety and tolerability profile. Enrollment is…
Spectral AI, Inc. announced the results of its 2026 Annual Meeting confirming all shareholder proposals, including board elections and audit firm ratification. The company highlighted its receipt of FDA De Novo classification for the DeepView System, enabling commercial distribution in the U.S. It also secured $31.7 million funding from BARDA, expa…
BCB Bancorp, Inc., a New Jersey-based community bank holding company, has appointed Thomas M. O'Brien as President and Chief Executive Officer effective June 1, 2026. O'Brien brings extensive experience in community banking and aims to address recent operational and credit challenges faced by the company while focusing on regulatory compliance, cos…
Lyell Immunopharma announced that its senior management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026, highlighting its progress in developing next-generation CAR T-cell therapies for cancer, and revealing its commercial manufacturing capacity to support product launches.
ALX Oncology Holdings Inc., a clinical-stage biotech company focusing on novel cancer treatments, announced its participation in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The company highlighted its lead candidate evorpacept, advancing through multiple clinical trials, and its second candidate ALX2004 currently in a Phase …
MAIA Biotechnology presented a Trial in Progress poster at the 2026 ASCO Annual Meeting detailing its pivotal Phase 3 clinical trial THIO-104, evaluating the efficacy of its novel telomere-targeting agent ateganosine in combination with checkpoint inhibitors for third-line treatment in non-small cell lung cancer patients resistant to current therap…
Outdoor Holding Company (Nasdaq: POWW), the owner of GunBroker.com, appointed Erich Buerger as Director of AI Strategy & Implementation to lead the company’s AI initiatives. This strategic hire aims to enhance marketplace functionality, operational efficiency, and long-term shareholder value through disciplined AI deployment aligned with the compan…
Kaltura has been named an Exemplary Provider in the ISG Research Buyers Guide on Conversational AI Emerging Providers. This accolade recognizes Kaltura's innovative conversational and agentic AI platform that enables personalized, real-time, context-aware digital engagement across multiple sectors. The company is expanding its AI capabilities throu…
Beyond Air, Inc. announced that the Nasdaq Hearings Panel has approved its request to continue listing on Nasdaq, provided the company regains compliance with the bid price requirement by July 31, 2026. The company plans to hold a shareholder vote on a reverse stock split to meet this requirement and remains focused on advancing its commercial and …
Agora, Inc., a leader in conversational AI and real-time engagement technology, announced that its CEO Tony Zhao intends to invest up to $20 million in the company’s shares over the next 12 months. This management share purchase plan aims to demonstrate confidence in the company's growth prospects amid expanding market opportunities in real-time en…
Immatics N.V. presented extended Phase 1b clinical trial data for its anzu-cel (IMA203) PRAME-targeted TCR T-cell therapy at the 2026 ASCO Annual Meeting, showing rapid, deep, and durable anti-tumor responses in heavily pretreated metastatic melanoma patients, including cutaneous and uveal subtypes. The therapy demonstrated a 56% confirmed overall …
Viasat Inc. has been selected by Lockheed Martin to supply high-bandwidth satellite communications technology for NOAA’s next-generation C-130J 'Hurricane Hunter' aircraft. This contract involves delivering Viasat's Hybrid SATCOM Approach technology to enable resilient, real-time data transmission supporting hurricane forecasting and severe weather…
